Going viral: HBV-specific CD8+ tissue-resident memory T cells propagate anti-tumor immunity

Jessica Wei; Jeffrey J Ishizuka

doi:10.1016/j.immuni.2021.07.014

Going viral: HBV-specific CD8⁺ tissue-resident memory T cells propagate anti-tumor immunity

Immunity. 2021 Aug 10;54(8):1630-1632. doi: 10.1016/j.immuni.2021.07.014.

Authors

Jessica Wei¹, Jeffrey J Ishizuka²

Affiliations

¹ Departments of Neurology and Immunobiology, Yale School of Medicine, New Haven, CT, USA; Department of Internal Medicine (Oncology), Yale Cancer Center, Yale School of Medicine, New Haven, CT, USA.
² Department of Internal Medicine (Oncology), Yale Cancer Center, Yale School of Medicine, New Haven, CT, USA. Electronic address: jeffrey.ishizuka@yale.edu.

PMID: 34380061
DOI: 10.1016/j.immuni.2021.07.014

Abstract

The nature of the epitopes recognized by tumor-infiltrating T cells is not clearly defined. In this issue of Immunity, Cheng et al. demonstrate that tissue-resident memory CD8⁺ T cells specific for hepatitis B virus-derived antigens exhibit potent anti-tumor properties and correlate with relapse-free survival in patients with resected hepatocellular carcinoma.

Publication types

Comment

MeSH terms

CD8-Positive T-Lymphocytes
Carcinoma, Hepatocellular*
Hepatitis B virus
Humans
Liver Neoplasms*
Neoplasm Recurrence, Local

Grants and funding

K08 CA245112/CA/NCI NIH HHS/United States